Efficacy and safety of celecoxib on the incidence of recurrent colorectal adenomas: a systematic review and meta-analysis

References

• FerlayJSoerjomataramIDikshitRCancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012Int J Cancer20151365E359E38625220842
   PubMed Web of Science ®Google Scholar
• StrumWBColorectal adenomasN Engl J Med2016374111065107526981936
   PubMed Web of Science ®Google Scholar
• LiebermanDARexDKWinawerSJGiardielloFMJohnsonDALevinTRGuidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal CancerGastroenterology2012143384485722763141
   PubMed Web of Science ®Google Scholar
• HooverSSubramanianSTangkaFKLPatients and caregivers costs for colonoscopy-based colorectal cancer screening: experience of low-income individuals undergoing free colonoscopiesEval Program Plann201762818628153341
   PubMed Web of Science ®Google Scholar
• SubramanianSBobashevGMorrisRJWhen budgets are tight, there are better options than colonoscopies for colorectal cancer screeningHealth Aff201029917341740
   Web of Science ®Google Scholar
• NgSCWongSHColorectal cancer screening in AsiaBr Med Bull2013105294223299409
   PubMed Web of Science ®Google Scholar
• CottetVJoosteVFournelIBouvierAMFaivreJBonithon-KoppCLong-term risk of colorectal cancer after adenoma removal: a population-based cohort studyGut20126181180118622110052
   PubMed Web of Science ®Google Scholar
• DulaiPSSinghSMarquezEChemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysisBMJ2016355i618827919915
   PubMedGoogle Scholar
• VeettilSKTeerawattanapongNChingSMEffects of chemo-preventive agents on the incidence of recurrent colorectal adenomas: a systematic review with network meta-analysis of randomized controlled trialsOnco Targets Ther2017102689270028579807
   PubMed Web of Science ®Google Scholar
• VeettilSKLimKGChingSMSaokaewSPhisalprapaPChaiyakunaprukNEffects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs on the incidence of recurrent colorectal adenomas: a systematic review with meta-analysis and trial sequential analysis of randomized clinical trialsBMC Cancer201717176329137605
   PubMedGoogle Scholar
• RostomADubéCLewinGNonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task ForceAnn Intern Med2007146537638917339623
   PubMed Web of Science ®Google Scholar
• DubéCRostomALewinGThe use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task ForceAnn Intern Med2007146536537517339622
   PubMed Web of Science ®Google Scholar
• BelloAEHoltRJCardiovascular risk with non-steroidal anti-inflammatory drugs: clinical implicationsDrug Saf2014371189790225079141
   PubMed Web of Science ®Google Scholar
• BresalierRSSandlerRSQuanHCardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trialN Engl J Med2005352111092110215713943
   PubMed Web of Science ®Google Scholar
• BombardierCLaineLReicinAComparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study GroupN Engl J Med2000343211520152811087881
   PubMed Web of Science ®Google Scholar
• SilversteinFEFaichGGoldsteinJLGastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety StudyJAMA2000284101247125510979111
   PubMed Web of Science ®Google Scholar
• ChanFKLLanasAScheimanJBergerMFNguyenHGoldsteinJLCelecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trialLancet2010376973617317920638563
   PubMed Web of Science ®Google Scholar
• AschenbrennerDSCardiovascular risk of celecoxib no worse than that of ibuprofen or naproxenAm J Nurs20181181019
   Web of Science ®Google Scholar
• SolomonSDWittesJFinnPVCardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysisCirculation2008117162104211318378608
   PubMed Web of Science ®Google Scholar
• KearneyPMBaigentCGodwinJHallsHEmbersonJRPatronoCDo selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trialsBMJ200633275531302130816740558
   PubMed Web of Science ®Google Scholar
• GrahamDCampenDHuiRRisk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control studyLancet2005365945847548115705456
   PubMed Web of Science ®Google Scholar
• MeekILMartAFJ van de LaarVonkemanHENon-steroidal anti-inflammatory drugs: an overview of cardiovascular risksPharmaceuticals2010372146216227713346
   PubMedGoogle Scholar
• ArberNEagleCJSpicakJCelecoxib for the prevention of colorectal adenomatous polypsN Engl J Med2006355988589516943401
   PubMed Web of Science ®Google Scholar
• BertagnolliMMEagleCJZauberAGCelecoxib for the prevention of sporadic colorectal adenomasN Engl J Med2006355987388416943400
   PubMed Web of Science ®Google Scholar
• NissenSEYeomansNDSolomonDHCardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritisN Engl J Med2016375262519252927959716
   PubMed Web of Science ®Google Scholar
• McgettiganPHenryDCardiovascular risk and inhibition of cyclo-oxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase2JAMA2006296131633164416968831
   PubMed Web of Science ®Google Scholar
• VeettilSKSaokaewSLimKGChingSMPhisalprapaPChaiyakunaprukNComparative effectiveness of chemopreventive interventions for colorectal cancer: protocol for a systematic review and network meta-analysis of randomised controlled trialsJ Gastrointest Oncol20167459560227563450
   PubMedGoogle Scholar
• MoherDLiberatiATetzlaffJAltmanDGPRISMA GroupPreferred reporting items for systematic reviews and meta-analyses: the PRISMA statementAnn Intern Med20091514W64264269
   PubMed Web of Science ®Google Scholar
• ShortMWLaytonMCTeerBNDomagalskiJEColorectal cancer screening and surveillanceAm Fam Physician20159129310025591210
   PubMed Web of Science ®Google Scholar
• ArberNSpicakJRáczIFive-year analysis of the prevention of colorectal sporadic adenomatous polyps trialAm J Gastroenterol201110661135114621503000
   PubMed Web of Science ®Google Scholar
• BertagnolliMMEagleCJZauberAGFive-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib TrialCancer Prev Res200924310321
   PubMed Web of Science ®Google Scholar
• BaronJASandlerRSBresalierRSA randomized trial of rofecoxib for the chemoprevention of colorectal adenomasGastroenterology200613161674168217087947
   PubMed Web of Science ®Google Scholar
• HigginsJPTSterneJACSavovicJA revised tool for assessing risk of bias in randomized trialsCochrane Database Syst Rev201610Suppl 13
   Google Scholar
• DersimonianRLairdNMeta-analysis in clinical trials revisitedContemp Clin Trials201545Pt A13914526343745
   PubMed Web of Science ®Google Scholar
• HigginsJPThompsonSGDeeksJJAltmanDGMeasuring inconsistency in meta-analysesBMJ2003327741455756012958120
   PubMed Web of Science ®Google Scholar
• MelsenWGBootsmaMCRoversMMBontenMJThe effects of clinical and statistical heterogeneity on the predictive values of results from meta-analysesClin Microbiol Infect201420212312924320992
   PubMed Web of Science ®Google Scholar
• SterneJASuttonAJIoannidisJPRecommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trialsBMJ2011343d400221784880
   PubMed Web of Science ®Google Scholar
• AntmanEMBennettJSDaughertyAUse of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart AssociationCirculation2007115121634164217325246
   PubMed Web of Science ®Google Scholar
• BrozekJLAlkEAAlonso-CoelloPGrading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventionsAllergy200964566967719210357
   PubMed Web of Science ®Google Scholar
• MartínezMEBaronJALiebermanDAA pooled analysis of advanced colorectal neoplasia diagnoses after colonoscopic polypectomyGastroenterology2009136383284119171141
   PubMed Web of Science ®Google Scholar
• ThompsonPAAshbeckELRoeDJCelecoxib for the prevention of colorectal adenomas: results of a suspended randomized controlled trialJ Natl Cancer Inst201610812djw15127530656
   PubMedGoogle Scholar
• Coxib and traditional NSAID Trialists’ (CNT) Collaboration Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trialsLancet2013382989476977923726390
   PubMed Web of Science ®Google Scholar
• GunterBRButlerKAWallaceRLSmithSMHarirforooshSNon-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysisJ Clin Pharm Ther2017421273828019014
   PubMed Web of Science ®Google Scholar
• SolomonSDPfefferMAMcmurrayJJVEffect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomasCirculation2006114101028103516943394
   PubMed Web of Science ®Google Scholar
• GrosserTFriesSFitzgeraldGABiological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunitiesJ Clin Invest2006116141516395396
   PubMed Web of Science ®Google Scholar
• YuYRicciottiEScaliaRVascular COX-2 modulates blood pressure and thrombosis in miceSci Transl Med20124132132ra54
   PubMedGoogle Scholar
• GrosserTRicciottiEFitzgeraldGAThe cardiovascular pharmacology of nonsteroidal anti-inflammatory drugsTrends Pharmacol Sci201738873374828651847
   PubMed Web of Science ®Google Scholar
• HanifRPittasAFengYEffects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathwayBiochem Pharmacol19965222372458694848
   PubMed Web of Science ®Google Scholar
• Bibbins-DomingoKAspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force Recommendation StatementAnn Intern Med20161641283684527064677
   PubMed Web of Science ®Google Scholar
• VeettilSKJinatongthaiPNathisuwanSEfficacy and safety of chemopreventive agents on colorectal cancer incidence and mortality: systematic review and network meta-analysisClin Epidemiol2018101433144530349391
   PubMed Web of Science ®Google Scholar